Scandinavian ChemoTech’s subsidiary Vetiqure AB installs TSE and initiates treatments in USA
Vetiqure AB has conducted training and installation of the TSE therapy at FloridaWild Veterinary Hospital in Florida, USA.
The training was performed by Danny Nesrallah, the Company’s Business Development Manager & Consultant in North America, who has spent two days with the entire team. During the second day the training ended with a guided TSE treatment of a dog suffering from a nerve sheath tumor in its front paw.
During the training six DVM’s and three veterinary nurses started their training to become certified operators and supportive staff for the TSE therapy.
Vetiqure AB and FloridaWild has previously signed a contract which states the aim for FloridaWild to fully acquire the vetIQure™ device after the six-month evolution period that has just started. The long-term goal for the project is for both parties to establish a Centre of Excellence in order to perform future trainings, certifications of new DVMs that wish to become users of TSE.
"We are excited to be a part of exploring the options that we have to offer our cancer patients!"- says Dr. Pamela Schrager at FloridaWild Veterinary Hospital
“I am very happy that I had the opportunity to attend this important event in the history of Vetiqure AB. The momentum is continuously very strong for our Animal Care business both in Scandinavia and North America. As I have expressed before; Vetiqure AB has a good chance to outperform both internal and external targets this year.” - says Mohan Frick CEO for ChemoTech and Vetiqure
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
info@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation (TSE™), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
